ArticleEuropean journal of nuclear medicine and molecular imaging2026
Clinical value of per-treatment whole-body single-time-point automated dosimetry for [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence across oncologic theranostics: evidence for patient stratification, dosimetry, and adaptive radiopharmaceutical therapy.Frontiers in nuclear medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo assess the clinical value of single-time-point dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
methodsFifty-nine patients with progressive mCRPC expressing PSMA and previously treated with androgen receptor pathway inhibitors and taxane-based chemotherapy were retrospectively analysed. SPECT/CT imaging was performed after the first (C1) and fourth (C4) [¹⁷⁷Lu]Lu-PSMA-617 infusions on 360°-CZT camera. Automated segmentation and dosimetry protocols were applied to quantify absorbed doses in bone marrow and lesions. Dose-effect relationships were assessed using blood counts, PSA responses (PSA50 criteria), and PET imaging. Statistical analyses included Spearman correlation, Wilcoxon signed-rank test, and logistic regression.
resultsBone marrow absorbed dose (BMAD) at C1 was significantly correlated with red blood cells (RBC, ρ = -0.3) and haemoglobin (ρ = -0.26) decline. A higher BMAD was associated with greater declines in RBC count (median [IQR] 0.31 [0.33] Gy vs. 0.076 [0.19], p < 0.05) and haemoglobin (0.29 [0.41] vs. 0.092 [0.20], p = 0.056). A moderate negative correlation was found between PSA variation and total metastatic tumour absorbed (TMTAD) dose at C1 (ρ = -0.35) and from C1 to C4 (ρ = -0.35). Response modelling (based on PSA50) estimated 50% and 80% probabilities of response at 8.8 Gy and 18.1 Gy for TMTAD(C1) and at 11.3 Gy and 31.7 Gy for TMTAD(C1-C4).
conclusionSingle-time-point dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 therapy in mCRPC is clinically relevant, demonstrating dose-dependent haematological decline and therapeutic response. This approach has the potential to facilitate more personalised and accessible radioligand therapy.
Indexed as
Identifiers
41792565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.